Trials / Completed
CompletedNCT00428766
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Morphotek · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to establish the safest dose of MORAb-003 in subjects with advanced ovarian cancer. MORAb-003 is an antibody directed to an antigen on the surface of ovarian cancer cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MORAb-003 |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-01-30
- Last updated
- 2013-11-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00428766. Inclusion in this directory is not an endorsement.